JP2017537105A - 瘻孔を伴うクローン病の治療用ベドリズマブ - Google Patents

瘻孔を伴うクローン病の治療用ベドリズマブ Download PDF

Info

Publication number
JP2017537105A
JP2017537105A JP2017528845A JP2017528845A JP2017537105A JP 2017537105 A JP2017537105 A JP 2017537105A JP 2017528845 A JP2017528845 A JP 2017528845A JP 2017528845 A JP2017528845 A JP 2017528845A JP 2017537105 A JP2017537105 A JP 2017537105A
Authority
JP
Japan
Prior art keywords
fistula
weeks
humanized antibody
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017528845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537105A5 (enExample
Inventor
エル． ラッシュ，カレン
エル． ラッシュ，カレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017537105A publication Critical patent/JP2017537105A/ja
Publication of JP2017537105A5 publication Critical patent/JP2017537105A5/ja
Priority to JP2021153317A priority Critical patent/JP7579227B2/ja
Priority to JP2024127719A priority patent/JP2024161423A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017528845A 2014-11-26 2015-11-25 瘻孔を伴うクローン病の治療用ベドリズマブ Withdrawn JP2017537105A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021153317A JP7579227B2 (ja) 2014-11-26 2021-09-21 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2024127719A JP2024161423A (ja) 2014-11-26 2024-08-02 瘻孔を伴うクローン病の治療用ベドリズマブ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084815P 2014-11-26 2014-11-26
US62/084,815 2014-11-26
PCT/US2015/062705 WO2016086147A1 (en) 2014-11-26 2015-11-25 Vedolizumab for the treatment of fistulizing crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153317A Division JP7579227B2 (ja) 2014-11-26 2021-09-21 瘻孔を伴うクローン病の治療用ベドリズマブ

Publications (2)

Publication Number Publication Date
JP2017537105A true JP2017537105A (ja) 2017-12-14
JP2017537105A5 JP2017537105A5 (enExample) 2019-01-10

Family

ID=54834962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017528845A Withdrawn JP2017537105A (ja) 2014-11-26 2015-11-25 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2021153317A Active JP7579227B2 (ja) 2014-11-26 2021-09-21 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2024127719A Pending JP2024161423A (ja) 2014-11-26 2024-08-02 瘻孔を伴うクローン病の治療用ベドリズマブ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021153317A Active JP7579227B2 (ja) 2014-11-26 2021-09-21 瘻孔を伴うクローン病の治療用ベドリズマブ
JP2024127719A Pending JP2024161423A (ja) 2014-11-26 2024-08-02 瘻孔を伴うクローン病の治療用ベドリズマブ

Country Status (4)

Country Link
US (3) US20170327584A1 (enExample)
EP (2) EP3224280A1 (enExample)
JP (3) JP2017537105A (enExample)
WO (1) WO2016086147A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
MA45245A (fr) * 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
EP3552632B1 (en) 2016-12-07 2023-07-12 Stelic Institute & Co., Inc. Medicinal composition for treating and preventing inflammatory bowel disease
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
TWI775182B (zh) * 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
US20230142437A1 (en) 2020-03-18 2023-05-11 Millennium Pharmaceuticals, Inc. Devices and methods for treating a fistula
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2026019692A2 (en) 2024-07-15 2026-01-22 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
JP2008546397A (ja) * 2005-06-24 2008-12-25 セリェリクス、ソシエダッド、リミターダ 瘻の治療における脂肪組織由来間質幹細胞の使用
WO2013181694A1 (en) * 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
MX9706049A (es) 1995-02-10 1998-02-28 Leukosite Inc Adresinas vasculares mucosas y sus usos.
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
MXPA04011465A (es) 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
ATE517102T1 (de) 2002-11-18 2011-08-15 Chemocentryx Inc Arylsulfonamide
DE602005026779D1 (de) 2004-01-09 2011-04-21 Pfizer ANTIKÖRPER GEGEN MAdCAM
MX337423B (es) 2004-09-03 2016-03-04 Genentech Inc Antagonistas anti-beta7 humanizados y usos para los mismos.
WO2007061679A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
NZ595464A (en) 2009-03-20 2013-08-30 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
SMT201700515T1 (it) 2011-05-02 2018-01-11 Millennium Pharm Inc Formulazione per anticorpo anti- 4 7
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
MA45245A (fr) 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
CA3061320A1 (en) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
AU2018274749B2 (en) 2017-05-26 2025-05-22 Millennium Pharmaceuticals, Inc. Methods for the treatment of chronic pouchitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546397A (ja) * 2005-06-24 2008-12-25 セリェリクス、ソシエダッド、リミターダ 瘻の治療における脂肪組織由来間質幹細胞の使用
WO2008150490A2 (en) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriasis and crohn's disease
WO2013181694A1 (en) * 2012-06-04 2013-12-12 Gaurav Agrawal Compositions and methods for treating crohn's disease and related conditions and infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, vol. 147, JPN6019038142, September 2014 (2014-09-01), pages 618 - 627, ISSN: 0004506492 *
HOTOKEZAKA MASAYUKI: "RESULTS OF SETON DRAINAGE AND INFLIXIMAB INFUSION FOR COMPLEX ANAL CROHN'S DISEASE", HEPATO-GASTROENTEROLOGY, vol. VOL:58, NR:109, JPN5017010230, July 2011 (2011-07-01), pages 1189 - 1192, ISSN: 0004506491 *
WILLIAM J SANDBORN: "VEDOLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN'S DISEASE", NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:369, NR:8, JPN5017010231, 22 August 2013 (2013-08-22), US, pages 711 - 721, ISSN: 0004506490 *

Also Published As

Publication number Publication date
JP2024161423A (ja) 2024-11-19
EP3581585A1 (en) 2019-12-18
US20200031937A1 (en) 2020-01-30
JP2022023051A (ja) 2022-02-07
US20170327584A1 (en) 2017-11-16
US11884731B2 (en) 2024-01-30
JP7579227B2 (ja) 2024-11-07
EP3224280A1 (en) 2017-10-04
WO2016086147A1 (en) 2016-06-02
US20240376210A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
JP7579227B2 (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
JP7474287B2 (ja) 炎症性腸疾患の治療を目的とする三剤併用療法
JP6942053B2 (ja) 原発性硬化性胆管炎を治療する方法
US20230118596A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof
TW201735949A (zh) 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
JP2024069230A (ja) 慢性回腸嚢炎の治療のための方法
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
US20250282875A1 (en) Methods of treating colorectal cancer using an anti-ctla4 antibody
US20230035183A1 (en) Antibodies for the treatment of chronic graft versus host disease
CN114423455A (zh) 用于治疗系统性硬化症的药物组合物
US20250333509A1 (en) Methods for treating cancer, or von-hippel lindau disease using a combination of a tigit antagonist, a pd-1 antagonist, and a hif-2-alpha inhibitor
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
WO2025072725A1 (en) Methods for the treatment of cardiovascular disease
WO2023196153A1 (en) Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist
CN118055761A (zh) 包含tigit拮抗剂、pd-1拮抗剂和化学治疗剂的治疗组合
BR122024027186A2 (pt) Anticorpo que se liga especificamente ao receptor de interleucina 6 (il-6), seu uso e composição farmacêutica, medicamento ou kit
IL271284B (en) Methods of treating or preventing asthma by administering an antagonist to -il-r4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190611

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210921

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211005

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20211105